New Codes for Cytokine Release Syndrome (CRS)

October 1st, 2020 - Wyn Staheli, Director of Research
Categories:   Diagnosis Coding   Allergy|Immunology   Anesthesia|Pain Management   Cardiology|Vascular   Endocrinology   Home Health|Hospice   Neurology|Neurosurgery   Oncology|Hematology   Rheumatology  
0 Votes - Sign in to vote or comment.

Cytokine release syndrome (CRS), sometimes referred to as a cytokine storm, is a systemic inflammatory response triggered by a variety of reasons such as infections, certain drugs, or after treatment with some types of immunotherapy, (e.g., monoclonal antibodies and CAR-T cells).  It is characterized by a large, rapid release of cytokines into the blood. Cytokines are small proteins that help cells around the body communicate. When the immune system detects a threat, cells release cytokines to coordinate the body’s response. Too many cytokines cause harmful levels of inflammation throughout the body. Symptoms of CRS may include nausea, headache, tachycardia, hypotension, rash, shortness of breath, or in severe cases, death.

Chimeric Antigen Receptor T (CAR-T) Cell Therapy is an advancement in the treatment of relapsed or refractory leukemia and large b-cell lymphoma. In some instances complications of the therapy have been observed. Two of the most prevalent complications are Cytokine Release Syndrome (CRS) and Immune effector Cell Associated Neurotoxicity Syndrome (ICANS). 

In 2019, the American Society for Transplantation and Cellular Therapy (ASTCT) published a paper regarding the formal consensus for grading both CRS and ICANS. With this new consensus on grading, unique ICD-10-CM diagnosis codes were created to more effectively track the severity of patient symptoms in response to immune effector cell (IEC) therapy. 

The following table summarizes the new grading based on the consensus paper in the References. For additional information, see the consensus paper (see References below).

CRS Consensus Grading Table

CRS Parameter

Grade 1 (D89.831)

Grade 2 (D89.832)

Grade 3 (D89.833)

Grade 4 (D89.834)

Fever1

Temperature >38° C

Temperature >38° C

Temperature >38° C

Temperature >38° C

 

With

Hypotension

None

Not requiring vasopressors

Requiring a vasopressor with or without vasopressin

Requiring multiple vasopressors (excluding vasopressin)

 

And/or2

Hypoxia

None

Requiring low-flow nasal cannula3 or blow-by

Requiring high-flow nasal cannula3, facemask, nonrebreather mask, or Venturi mask

Requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)

Notes:

  1. Fever is defined as temperature ≥38°C not attributable to any other cause. In patients who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia.
  2. CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
  3. Low-flow nasal cannula is defined as oxygen delivered at ≤6L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics.
  4. High-flow nasal cannula is defined as oxygen delivered at >6L/minute.
  5. Grade 5 (G89.8335) is defined as death due to CRS in which another cause is not the principle factor leading to this outcome.

It should be noted that, although ICD-10-CM codes were requested which further describe the grade levels for Immune effector cell-associated neurotoxicity syndrome (ICANS), at the time of publication there are no new codes for that syndrome. 

ICD-10-CM instructional notes specify that any underlying cause (e.g., complications following infusion and therapeutic injection [T80.89-], complications of transplanted organs and tissue [T86.-]) should be coded before using these new D89.83- codes. Associated manifestations should also be coded.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association